Quick Answer
Adaptimmune Therapeutics PLC reported Long-Term Debt of $50.24 million for fiscal year 2024.
Adaptimmune Therapeutics PLC Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $50.24M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $25.68M | +2.9% | +1.0% |
| March 31, 2025 | $25.41M | — | -49.4% |
| December 31, 2024 | $50.24M | — | +0.7% |
| September 30, 2024 | $49.87M | — | +99.8% |
| June 30, 2024 | $24.95M | — | — |
- The most recent figure is from Adaptimmune Therapeutics PLC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: